Sermorelin and tesamorelin both act through growth-hormone-releasing hormone signaling, but they are different medicines with different evidence and regulatory histories. A question such as “which is stronger?” skips the more important issue: what condition is being treated and which product has evidence for it?
Tesamorelin has an FDA-approved product for reducing excess abdominal fat in adults with HIV-associated lipodystrophy. That indication does not make it a general weight-loss drug or establish that compounded sermorelin produces the same result. Neither treatment should be selected from a bodybuilding comparison chart alone.
These are different GHRH analogs. Tesamorelin’s approved indication is specific, and its evidence should not be transferred to compounded sermorelin.
The main differences at a glance
Swipe sideways to read the full table. You can also select the table and use the arrow keys.
| Question | Sermorelin | Tesamorelin |
|---|---|---|
| Broad mechanism | GHRH analog | Different GHRH analog |
| Product context | Historical GEREF and current compounded preparations | Approved EGRIFTA products, with formulation-specific labels |
| General anti-aging approval | No current compounded product approval for this use | The specific approved indication is not general anti-aging |
| Interchangeable dose? | No | No |
The EGRIFTA WR label states that the product is not indicated for weight-loss management and notes limitations including long-term cardiovascular safety uncertainty. Its instructions also apply to that formulation. Even different tesamorelin presentations should not be substituted without the prescriber's and pharmacist's directions.
Visceral-fat evidence has a defined setting
HIV-associated lipodystrophy is a specific clinical situation. A result in that population cannot be assumed to predict belly-fat reduction in an otherwise healthy person or someone with a different cause of weight gain.
Our weight-loss guide explains why changes in visceral fat, total weight, and body composition are different endpoints. If fat loss is the goal, ask about treatments with evidence for your diagnosis rather than treating all growth-hormone-related medicines as equivalents.
Why sermorelin's history also needs precision
The 2013 Federal Register determination found that specified GEREF products were not withdrawn for reasons of safety or effectiveness. It does not approve today's compounded injections, tablets, or sprays for adult wellness.
The FDA's compounding explanation is the relevant starting point for understanding current compounded products. A historical approval associated with an ingredient should not be presented as approval of every later preparation or use.
Safety questions can overlap without being identical
EGRIFTA WR's label discusses active malignancy, disruption of the hypothalamic-pituitary axis, pregnancy, hypersensitivity, increased IGF-1, glucose intolerance, and other risks. These details belong to its prescribing information, not an invented FDA label for sermorelin.
They do show why medical history and monitoring matter in GH-pathway treatment. Ask the clinician to explain which concerns apply to the actual product proposed and how diabetes, cancer history, or pituitary disease affects the decision.
Which is better for muscle growth or recovery?
There is no universal winner established for bodybuilding or healthy-aging use. A drug producing a larger hormone response is not necessarily producing better strength, function, or quality of life. The hormones-and-aging statement helps put those claims into perspective.
Adding ipamorelin creates yet another comparison. Our sermorelin versus ipamorelin guide distinguishes its mechanism and evidence gaps rather than ranking all three by anecdotal reports.
Can you take them together?
Do not combine or alternate sermorelin and tesamorelin based on an online stack. Their shared pathway does not prove additional clinical benefit or establish a safe ratio. See the combination guide for the questions a prescriber should answer before considering multiple agents.
The useful comparison is diagnosis first, exact product second, evidence and monitoring third. Ask what outcome would justify treatment for you and what alternative would address the same concern with better-established benefits.
A combined plan needs a separate rationale
The focused sermorelin-and-tesamorelin guide addresses taking both agents, rather than choosing between them. It explains why an approved indication for one product and a shared signaling pathway do not validate a two-drug wellness protocol.
If cognition research is part of the pitch, read the clinical-studies guide. It distinguishes the studies that used sermorelin from those that used tesamorelin and keeps their findings tied to the correct intervention.
When the comparison also includes ipamorelin
The three-way comparison puts sermorelin, tesamorelin, and ipamorelin in one table while preserving their different evidence bases. It explains why a specific approved indication cannot become a universal ranking for general weight loss or anti-aging.
Sources & further reading
Provider pages describe offers; they do not independently establish treatment benefits. Sources checked September 20, 2026.
This article is education, not a diagnosis, prescription, or dosing plan. Discuss treatment and alternatives with a licensed clinician who knows your history. Compounded medications are not FDA-approved.